Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program

Notice ID:

HT9402-22-Q-0001(1)

Department/Ind. Agency:

DEPT OF DEFENSE

Sub-tier:

DEPT OF DEFENSE

Sub Command:

DEFENSE HEALTH AGENCY

Office:

DEFENSE HEALTH AGENCY

All Dates/Times are:

(UTC-06:00) CENTRAL STANDARD TIME, CHICAGO, USA

Updated Published Date:

(UTC-06:00) CENTRAL STANDARD TIME, CHICAGO, USA

Original Published Date:

2021-10-26 14:11:00

Original Response Date:

Nov 22, 2021 12:00 pm CST

Inactive Policy:

Manual

Original Inactive Date:

May 22, 2022

Initiative:

• None***--***

Product Service Code:

6505 - DRUGS AND BIOLOGICALS

NAICS Code:

325412 - Pharmaceutical Preparation Manufacturing

Original Set Aside:

Background: The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: February 2022: The following drug classes/subclass will be reviewed: Livmarli - Metabolic Agents - Miscellaneous Qulipta - Migraine Agents - NA Skytrofa - Growth Hormone Agents - NA The RFQ, including UF BPA and UF ADP appendices are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-22-Q-0001(1). Pre-proposal teleconference is on November 10, 2021, details are stated in Part 2.5. Pre-proposal teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.

MANAGED CARE CONTRACT DIRECTORATE 16401 E. CENTRETECH PKWY, ATTN: AEA

AURORA , CO 80011

USA

Primary Point of Contacts:

Madison Northen

Secondary Point of Contact:

Hudson Tompkins